Floatz logo

MOGAMULIZUMAB

Peripheral T/NK-cell Lymphoma

Kyowa Kirin Co., Ltd.monoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

36 Active assets in the Peripheral T/NK-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 2BB
ETOPOSIDE
Alliance for Clinical Trials in Oncology
Phase 4BB
DEXAMETHASONE
Zhengzhou University
Phase 4BB
Inno-206
City of Hope Medical Center
Phase 2BB
FILGRASTIM
City of Hope Medical Center
Phase 2BB

View all 50 →

Same molecule, other indications

MOGAMULIZUMAB is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
adult T-cell leukemia/lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
mycosis fungoidesDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →